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Abstract
Background: Our aim was to investigate the prevalence and clinical relevance of inherited complement and antibody
deficiency states in a large series of patients with various autoimmune rheumatologic diseases (ARD) with juvenile onset.
Methods: A total number of 117 consecutive patients from 2 tertiary referral hospitals were included in the study. All
patients underwent genetic screening for type I C2 deficiency and C4 allotyping. Serum levels of immunoglobulin classes
measured systematically throughout their regular medical care were recorded retrospectively.
Results: Our cohort of patients included 84 with juvenile idiopathic arthritis (JIA), 21 with systemic lupus erythematosus
(SLE), 6 with systemic vasculitis, 2 with juvenile scleroderma, 2 with idiopathic uveitis, 1 with mixed connective tissue
disease and 1 with SLE/scleroderma overlap syndrome. We have found 16 patients with evidence of primary
immunodeficiency in our series (13.7 %), including 7 with C4 deficiency, 5 with selective IgA deficiency, 3
with C2 deficiency and 2 with unclassified hypogammaglobulinemia (one also presented C4D). Of the 84
patients with JIA, 4 (4.8 %) had a complement deficiency, which was less prevalent than in the SLE cohort
(23.8 %), but all of them have exhibited an aggressive disease. Most of our patients with primary antibody
deficiencies showed a more complicated and severe disease course and even the co-occurrence of two associated
autoimmune diseases (SLE/scleroderma overlap syndrome and SLE/autoimmune hepatitis type 1 overlap).
Conclusions: Our findings among others demonstrate that complement and immunoglobulin immunodeficiencies
need careful consideration in patients with ARD, as they are common and might contribute to a more severe clinical
course of the disease.
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Background
Primary immunodeficiencies (PIDs) are an inherited group
of over 200 disorders that affect distinct components of the
innate and adaptive immune system and predispose af-
fected individuals to increased rate and severity of infection,
immune dysregulation with autoimmune disease and ma-
lignancy [1, 2]. Although they are generally recognized as
rare disorders, higher prevalence are expected with the im-
provement of PIDs analysis [3]. Unfortunately, PIDs are
widely underdiagnosed and undertreated [3]. Domain ex-
perts have done international collaborative efforts re-
cently in order to increase awareness about the importance
of early diagnosis and access to optimal care in these
patients [3].
A significant proportion of patients presenting with an
autoimmune condition have an underlying PID disorder
that may not be clinically relevant [4] yet it may contrib-
ute to a more aggressive and worse prognosis [5]. Con-
versely, at present, strong evidence exist in favor of the
notion that PIDs are more prevalent in patients with
autoimmune conditions than in general population. Se-
lective immunoglobulin A deficiency (SIgAD), the most
common PID, has an estimated incidence ranging be-
tween 1:143 and 1:875 in the general European popula-
tion, and much lower among Asian populations [6]. On
the other hand, Liblau et al. reported SIgAD in 4.3 % of
patients with juvenile idiopathic arthritis (JIA) [7],
whereas Cassidy et al. identified SIgAD in up to 5.2 % of
children with systemic lupus erythematosus (SLE) [8].
Other antibody deficiency syndromes have also been re-
ported in association with autoimmune rheumatologic
disorders (ARDs) as well. Complement deficiencies in-
volving components of the classical pathway (C1, C4 or
C2) have been recognized as one of the strongest genetic
risk factor for SLE [9, 10], but have also been described
with an increased frequency in rheumatoid arthritis
(RA) population [11]. However, studies that specifically
address the prevalence of complement deficiencies in
JIA patients, the most common childhood rheumatic
condition, are limited. One study of 35 JIA patients has
reported a prevalence of 14.3 % for C4 deficiencies [12]
and in another two studies, C4 allotyping was consid-
ered in JIA population in order to find genetic suscepti-
bility factors for the disease [13, 14].
The traditional diagnostics of complement deficiencies
using serum C3 and C4 levels and CH50 activity was
demonstrated not to be adequate to detect C4 and/or
C2 deficiency in one study of Boeckler et al. [15] on SLE
patients, allowing the diagnosis in a limited number of
cases. Instead, the authors recommend C4 protein allo-
typing and genetic screening for type I C2 deficiency to be
performed in investigative studies of primary complement
deficiency states. According to Johnson et al. [16] this mo-
lecular bias is the most common cause of inherited C2
deficiency, occurring in over 90 % of C2- deficient
individuals.
Therefore, we performed a prospective study in order to
assess the prevalence and clinical relevance of inherited
complement and antibody deficiency states in a large series
of patients with various ARDs with juvenile onset.
Methods
Study population
This was a prospective observational cohort study. A total
number of 117 consecutive patients with paediatric-onset
autoimmune rheumatologic diseases (ARD) were included
in the study. Our cohort of patients was recruited from 2
tertiary referral hospitals for rheumatologic patients across
Cluj-Napoca, Romania, over 1 year (Emergency Children’s
Hospital and the Rheumatology Unit of the Emergency
Clinical County Hospital). The study was approved by the
local Ethical Committee of the Iuliu Hatieganu University
of Medicine and Pharmacy. Written informed consent
has been obtained prior to their inclusion in the study
as appropriate.
The onset of disease before 16 years of age and a well
define diagnosis of ARD based on the revised ILAR cri-
teria for JIA [17], new SLICC classification criteria for
classification of SLE [18], EULAR/PRINTO/PRES classi-
fication criteria for childhood vasculitis [19], PRES/ACR/
EULAR provisional classification criteria for juvenile sys-
temic sclerosis (jSSc) [20] were the inclusion criteria. Pa-
tients with recent blood transfusions and incomplete or
unavailable medical records were excluded from this study.
Data collection
Medical records were obtained for evaluation from the
attending physician. Demographic characteristics, family
history of autoimmune diseases, PIDs and consanguinity,
patient medical history (in particular infectious events,
other associated autoimmune conditions, allergic diseases),
diagnosis and history of present illness, drug therapy his-
tory since disease onset, associated conditions and compli-
cations were recorded for each patient. With regard to
infections, we were interested in those that would arouse
suspicion of PID: recurrent bacterial infections, mycobac-
terial infections, chronic mucocutaneous or invasive fungal
infections and other opportunistic infections.
Furthermore, patient’s charts were retrospectively
reviewed for the immunological investigations performed
as part of the diagnosis process, before initiating immuno-
suppressive therapy and afterwards, during the period of
follow-up. Therefore, we registered the following immuno-
logical parameters: total serum levels of IgG, IgA, IgM, IgE,
C3, C4, circulating immune complexes (CIC) and rheuma-
toid factor (RF). All patients included in the study have had
C3, C4 and Ig levels tested at the diagnosis of AID. When
available, serum levels of IgG2 and IgG4 were also noted.
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In addition, the autoantibodies profile of patients focusing
on the antinuclear antibodies (ANA) panel, anti-cyclic
citrullinated peptide (CCP) antibodies, anti-dsDNA anti-
bodies (dsDNA), antiphospholipid antibodies (APLAs)
and organ-specific autoantibodies [anti-endomysium
(EmA), anti-gastric parietal cells (GPC), anti-smooth
muscle (ASMA), anti-mitochondrial (AMA), anti-
liver-kidney microsomal (LKM1), anti-thyroid perox-
idase (TPO)] was recorded too. The latter tests were
performed depending on the clinical symptoms and
anamnesis, according to the treating physician.
Reference ranges for the immunological tests analysed
by immunoturbidimetry were as follows: 90–180 mg/dl
for C3, 10–40 mg/dl for C4 and <18 IU/ml for RF. The
serum levels of Ig were interpreted based on patient’s
age. Autoantibodies test results were considered on their
relation to the reference range of specific laboratory
where the tests were done. The diagnosis of PID was
established based on the new clinical diagnosis criteria
for the European Society for Immunodeficiencies (ESID)
registry [21]. Accordingly, the clinical criteria for a prob-
able diagnosis of SIgAD were (1) at least one of the fol-
lowing: increased susceptibility to infection, autoimmune
manifestations, affected family member; (2) diagnosis
after 4th year of life; (3) undetectable serum IgA (when
measured with nephelometry less than 0.07 g/L) but
normal serum IgG and IgM (measured at least twice);
(4) secondary causes of hypogammaglobulinaemia have
been excluded; and (5) normal IgG antibody response to
vaccination [21]. Unclassified hypogammaglobulinaemias
was established in respect to the following criteria: (1)
one of the following: recurrent infections, autoimmune
phenomena (especially cytopenias), lymphoproliferation/
lymphoma; (2) marked decrease of at least one of IgG,
IgG subclass (es), IgA or IgM levels (measured at least
twice); (3) secondary causes of hypogammaglobulinae-
mia have been excluded; (4) normal isohaemagglutinins
or/ and antibody response to vaccines; and (5) normal
T-cells and normal naive T cells.
Genetic analyses
Blood sample collection for the genetic analyses was per-
formed during the routine visits in the hospital. Genomic
DNA was extracted from peripheral blood using a Wizard®
Genomic DNA Purification kit (Promega) according to
manufacturer instructions with minor modifications.
Detection of type I C2 deficiency
PCR technique was used to detect the type I C2 deficiency
(28 bp deletion that removes last 9 bp of exon 6 and first
19 bp of the intron 6, the translated protein is truncated).
The PCR reactions were performed in 25 μl containing
1.5 mM MgCl2, 0.2 mM dNTPs, 0.5 μM of each primer,
1U of Dream Taq polymerase (ThermoScientific) and
100 ng of gDNA. The primers and PCR amplification pro-
gram used were described previously [15]. The PCR prod-
ucts were detected by agarose gel electrophoresis (2 %).
Detection of C4 Deficiencies
The PCR reactions were performed in 25 μl as described
above for C2 deficiency. The primers used for PCR amp-
lification were described previously [22]. A touchdown
PCR was performed starting with initial denaturation at
95 °C for 4 min, followed by 6 cycles of 94 °C for 30 s,
68 °C - 1 °C/cycle, 72 °C for 40 s; and 35 cycles of 94 °C
for 30 s, 63 °C for 1 min, 72 °C for 40 s; final extension
5 min at 72 °C. The PCR products were detected by
agarose gel electrophoresis (1.5 %). Patients with normal
C4 alleles produced 2 fragments (377 and 578 bp) or no
PCR amplification at patients with C4 deficiencies.
Statistical methods
Numerical variables such as age and disease duration
were summarized by mean, median and range. Dichot-
omous variables were provided as frequency (in percent-
age). The overall infectious complication rate express
the percent of patients with significant infectious events
in different groups. Small subsets of patients with PID
did not allowed us to make any meaningful
comparisons.
Results
Our cohort included 84 patients with JIA (44 % female,
30 oligoarticular JIA, 23 polyarticular JIA, 18 systemic-
onset JIA, 9 enthesitis-related arthritis, 1 psoriatic arth-
ritis, 3 undifferentiated arthritis), 21 patients with SLE
(90 % female), 6 patients with systemic vasculitis (83 %
female), 2 patients with juvenile scleroderma (one boy
with localised scleroderma and one girl with jSSc), 2 pa-
tients with idiopathic uveitis (both boys), 1 girl with
mixed connective tissue disease (MCTD) and 1 girl with
SLE/localized scleroderma overlap syndrome. All of
them were Caucasions of European ancestry. Mean age
at autoimmune disease onset was 8 years old with range
between 0.7 and 16. Median duration of follow-up was
4 years, with range between 0.5 and 40 years.
We have found 16 patients with evidence of PID in
our series. The distribution of PIDs among various
juvenile-onset ARDs are presented in Table 1.
Out of the 16 PID patients, only 2 were boys. With the
exception of patient 6 and 7, our PIDs patients had no
family history of PID. The overall infectious complica-
tion rate was 43.75 % in the PID patients and only 5 %
in the cohort with no evidence of PID. The age at auto-
immune disease onset in the PID patients has ranged be-
tween 0.7 and 16 years of age. One SIgAD patient had
an infantile onset and four patients had the onset of
symptoms at 2–7 years of age. Duration of follow-up in
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the PID group was between 0.5 and 30 years. The diag-
nosis of inherited antibody deficiency was established
concomitant with the AID diagnosis in patient 1, 3, 4, 5
and 6 or previous to AID onset in patient 2 (at 8 years
old) and patient 7 (at 4 years old). The primary comple-
ment deficiencies were diagnosed at the time of this
study in all patients. Detailed clinical and immunological
characteristics of our PID patients and also the signifi-
cant infection episodes are described in Table 2.
Unclassified hypogammaglobulinaemia has been desig-
nated in two siblings (patient 6 and 7), both with ANCA-
negative systemic vasculitis. Both sisters have demon-
strated persistently reduced IgM [the mean IgM level dur-
ing the disease course was 11 mg/dl (range 5–22) in
patient 6 and 27 mg/dl (range 20–35) in patient 7; the
normal range for their age was 23–190 mg/dl in patient 6
and 50–260 mg/dl in patient 7] and IgA [the mean IgA
level was 9 mg/dl (range 2–18) in patient 6 and 20 mg/dl
(18–43) in patient 7; the normal range for their age was
23–190 mg/dl], decreased IgG4 (<0.6 mg/dl in patient 6
and 2 mg/dl in patient 7; normal range 3–157 mg/dl). Pa-
tient 6 also had reduced IgG2 (61 mg/dl, normal range
65–220 mg/dl) and complete C4BD. Total serum IgG
levels were not constantly reduced below 500 mg/dl in pa-
tients 6 and 7, although in patient 6 they were occasionally
decreased (the lowest value was 326 mg/dl).
Homozygous C2D was identified in one girl (patient 8)
with SLE onset at 12 years of age, prominent photoder-
matitis and articular involvement and positive anti-Ro
antibodies. Two other patients had heterozygous C2D
(patient 9 and 10). Patient 9 was a girl with SLE and sig-
nificant nephritis within 2 years after onset who under-
went renal transplantation. Patient 10 was a boy with RF
negative polyarticular JIA, with positive ANA in low titres,
with still on-going active arthritis eleven years after onset.
Complete C4B deficiency was found in four patients.
Apart from patient 6, there was one SLE female patient
(patient 11), one systemic JIA patient (patient 12) and
one girl with oligoarticular JIA (patient 13). Of the 3 pa-
tients with partial C4A deficiency, one had an undiffer-
entiated form of JIA (patient 16) and two patients had
SLE (patient 14 and 15). Notably, patient 15 had associ-
ated SLE and autoimmune hepatitis type I.
Patients with SIgAD had the following diagnoses: one
SLE/scleroderma overlap syndrome (IgA between 0 and
5 mg/dl), one SLE associated with autoimmune hepatitis
type I (IgA between 0 and 7 mg/dl), one systemic-onset JIA
(IgA between 2 and 6 mg/dl), one MCTD (IgA = 5 mg/dl),
one oligoarticular JIA (IgA = 4 mg/dl). Of note, two of
them associated allergic asthma.
Notably, the association of overall PID was greater in
the SLE patient population relative to the JIA group of
patients (28.6 % versus 7.2 %). In particular, C4D, C2D
and also SIgAD were more prevalent in SLE group of
patients than in the JIA cohort.
Among the 6 patients with positive RF in our JIA co-
hort, 2 were diagnosed with PID: patient 5 with SIgAD
and patient 16 with partial C4AD. Acute anterior uveitis
occurred in 9 JIA patients (2 with PID and 7 without PID).
Infectious events, associated autoimmune conditions other
than JIA, complications including macrophage activation
syndrome and secondary amyloidosis occurred in very low
numbers only in JIA population withough PID. The associ-
ated autoimmune diseases found in our JIA patients were
type I diabetes mellitus and autoimmune thyroiditis.
Two SLE-PID patients presented with pulmonary tu-
berculosis at 14 years (patient 15) and 35 years of age
(patient 14), respectively. It is important to note that in
both cases there were no other risk factors for acquiring
the infection. Moreover, two patients with SLE and PID
associated autoimmune hepatitis type I (patient 2 with
SIgAD and patient 15 with partial C4A D).
The small number of patients with PID did not allowed
us to make any meaningful comparisons regarding clinical
and immunological features of the disease.
Discussion
Over the past decades, there has been an increasing inter-
est in the field of immunopathology providing a better un-
derstanding of the mechanisms that underlie diseases such
as immunodeficiency, autoimmunity, autoinflammation or
cancer. This was reflected in adding new disease entities,













n (%) n (%) n (%) n (%) (n = 1)
PIDs 16 (13.7) 6 (7.2) 6 (28.6) 2 (33.3)a 1 1
C4D 7 (6) 3 (3.6) 3 (14.3) 1 (16.6) 0 0
C2D 3 (2.6) 1 (1.2) 2 (9.5) 0 0 0
SIgAD 5 (4.3) 2 (2.4) 1 (4.8) 0 1 1
Unclassified hypogamma globulinaemia 2 (1.7) 0 0 2 (33.3) 0 0
PID primary immunodeficiency, C4D C4 complement deficiency, C2D C2 complement deficiency, SIgAD selective immunoglobulin A deficiency
aOne patient with vasculitis has been diagnosed with hypogammaglobulinemia, also complete C4B deficiency
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Table 2 Clinical and immunological characteristics of the 16 patients with PID in our series










Associated conditions and complications
1 F SIgAD SLE/scleroderma overlap syndrome 5 for LS
16 for
SLE














2 F SIgAD SLE associated with autoimmune
hepatitis type 1












3 F SIgAD Systemic-onset JIA: polyarticular course,
chronic bilateral iridocyclitis with bilateral
cataract formation and band
keratopathy, loss of vision
0.7 16 ANAsa No
4 F SIgAD MCTD: polyarthritis, livedo reticularis,
Raynau d’s phenomenon, alopecia,
Gottron’s papules, rash of dermatomyositis,
one psychotic episo de, aseptic necrosis of
the hip, direct Coombs ’s test, intermittent
low C3 Allergic Asthma
14 13 ANAs, Esophageal
candidiasis after
AID therapydsDNA
U1 RNP Urinary tract
infections prior
to AID diagnosisANCAs
5 M SIgAD Undifferentiated JIA: oligoarthritis,
positive RF Allergic Asthma




Systemic vasculitis (ANCA negative):
fever, myalgia, a rthralgia, livedo reticularis,
maculopapular rash, III and VI cranial nerve
palsy, transient ischemic attack,
haemorrhagic stroke with right hemiparesis,
thrombocytopenia, nodular regenerative
hyperplasia of the liver, splenomegaly,
growth retardation




Systemic vasculitis (ANCA negative): fever,
myalgia, livedo reticularis, cutaneous
nodules, systemic arterial hypertension,
abdominal recurrent pain, massive
intestinal bleeding; bicuspid aortic valve
disease with aortic valve insufficiency




the age of 3
8 F Homozygous C2D SLE: photosensitive lupus rash, oral ulcers,
synovitis, perniosis, serum high CIC levels
12 2.5 ANAs No
SS-A, Ro 52
9 F Heterozygous C2 D SLE: malar rash, synovitis, lupus nephritis,
thrombocytopenia, leukopenia, hemolytic
anemia, low serum C3 and C4 levels, serum
high CIC levels, renal transplantation
12 2.5 ANAsb No
dsDNA
10 M Heterozygous C2 D Seronegative polyarticular JIA, Bronchogenic
cyst with surgical resection in infancy
8 11 ANAs in
low titersb
No
11 F Complete C4B deficiency SLE: lupus nephritis, polisynovitis,
photosensitive lupus rash, low serum C3
and C4 levels, serum high CIC levels,
secondary antiphospholipidic syndrome





12 F Complete C4B deficiency Systemic-onset JIA: fever, polyarthritis,
evanescent rash, myalgias
7 9 No No
13 F Complete C4B deficiency Oligoarticular JIA 1.5 0.5 No No
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modern diagnostic strategies and novel immunotherapies
that are being constantly developed. Although the
spectrum of PIDs has been steadily expanding, a substan-
tial number of patients remain undiagnosed.
We believe that this is the largest JIA cohort of pa-
tients investigated for both primary C2 and C4 comple-
ment components deficiencies. Of the 84 patients with
JIA evaluated in the present study, 4.8 % have had gen-
etic evidence of early complement deficiency, which was
less prevalent than in our SLE patients (23.8 %). This
may be regarded as a significant proportion, in compari-
son with the prevalence of complement deficiencies in
general population, which has been calculated to be
about 0.03 % (excluding MBL deficiency) [23]. In our
series, C4D has been associated with JIA in 3.6 % of the
cases, unlike the higher prevalence of 14.3 % reported in
one previous study [12], using the same previously de-
scribed primers for PCR amplification [22]. This variabil-
ity may be explained by the difference in the total
number of patients investigated (84 vs 35) or different
genetic background. The older studies offer divergent re-
sults regarding the association between JIA and null al-
leles at the C4A and C4B locus [13, 14]. Heterozygous
C2D was found in only one patient with seronegative
polyarticular JIA. There is a paucity of studies relating to
complement deficiencies in JIA. Gilliam et al. believe
that many researchers did not considered this associ-
ation, because polyarticular and oligoarticular JIA does
not have systemic vasculitis [12]. But, later on, the same au-
thors demonstrated complement activation with a domin-
ant role of the classical pathway in both polyarticular and
oligoarticular subtypes of JIA [24]. In addition, another re-
cent study found classical pathway up-regulated in systemic
JIA too [25]. This data suggest greater than anticipated con-
tributions of the complement pathways in the pathogenesis
of JIA, regardless of the subtype. Given all that, it seems
likely that dysregulation of the complement system in cases
with defects of the pathway’s components may exacerbate
the disease process, due to inappropriate activation of the
system and impaired dissolution of immune complexes that
cumulate and maintain the synovial inflammation. Indeed,
all our complement deficient JIA patients have had an ag-
gressive disease by chronic continuous or polyphasic arth-
ritis (patient 10 and 12), severe bilateral chronic iridocyclitis
with loss of vision (patient 16) and very early onset of the
disease (1.5 years of age in patient 13). Remarkably, none of
these patients had any clinical warning signs for PID, be-
sides the occurrence of autoimmune manifestations.
We have also found complement deficiencies in the
23.8 % of the SLE patients and in another systemic vas-
culitis patient with concomitant unclassified hypogam-
maglobulinaemia and complete C4B deficiency. This was
not surprising, since associations between systemic auto-
immune diseases and any of the early components of the
classical pathways are all recognised [23, 26]. For in-
stance, homozygous C2 deficiency, which is the most
frequent hereditary deficiency in classical complement
pathway, was estimated to be associated with systemic
autoimmune disease in around 15 to 40 % of the cases
[27]. Deficiencies of C4 are very rare but associated with
a higher prevalence of SLE (75 %) [26], and almost ex-
clusively with the deficiency of C4A isotype [28]. In our
SLE cases with C4D, 2 had a partial deficiency of the
C4A isotype and one had a complete deficiency of C4B
isotype. We did not observed in these patients a younger
age at disease onset as previously noted [29]. Moreover,
it has been suggested in complement deficient SLE pa-
tients less renal, pulmonary or pericardial involvement
and more prominent annular photosensitive skin rashes
[29]. On the contrary, we have noted severe lupus
Table 2 Clinical and immunological characteristics of the 16 patients with PID in our series (Continued)
14 F Partial C4A deficiency SLE: Raynaud phenomena, lupus nephritis,
systemic arterial hypertension, secondary
vasculitis, synovitis, livedo reticularis,
pericarditis, secondary antiphospholipidic
syndrome, low serum C3 and C4 levels








15 F Partial C4A deficiency SLE associated with autoimmune hepatitis
type 1: fever, synovitis, lupus malar rash,
oral ulcers, serositis, haemolytic anaemia,
secondary cutaneous vasculitis, Libman-
Sacks endocarditis





16 F Partial C4A deficiency Undifferentiated JIA: oligoarthritis, positive
RF, bilateral chronic iridocyclitis with loss of
vision
7.3 3 ANAs§ No
AIH autoimmune hepatitis, ACA anti-cardiolipin antibodies, ANAs antinuclear antibodies, C4D C4 deficiency, C2D C2 deficiency; CVID common variable immunodeficiency,
dsDNA antibodies to double stranded DNA, F female, Ig Immunoglobulin, JIA Juvenile Idiopathic Arthritis, LS localized scleroderma, M male, MCTD mixed connective tissue
disease, RF rheumatoid factor, SIgAD selective IgA deficiency, SLE systemic lupus erythematosus, β2 GP anti-β2-glycoprotein I antibodies
aNegative ANA profile test (immunoblot), despite high titers of ANAs on indirect immunofluorescence (1/1280; homogeneous pattern)
bANAs profile not available
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nephritis within two years after onset in two girls with
heterozygous C2D and complete C4BD and mild lupus
nephritis with a later onset during the disease course in
the patient with partial C4AD. But patient 8 has adhered
more closely to the earlier described pattern of SLE pa-
tients with homozygous C2D: dominate photosensitivity
and articular involvement, no renal disease, presence of
anti-Ro antibodies [26].
Primary antibody deficiencies that we have found in
our cohort of patients consisted of 5 SIgAD cases and 2
unclassified hypogammaglobulinaemias in two siblings.
Our data regarding the prevalence of SIgAD in our JIA
and SLE patients were more consistent with the previous
studies [5, 7, 8]. It is important to note that most of anti-
body deficient patients showed a more complicated and
severe disease course, which may be, at least in part, an
effect of the associated PID. Remarkably, one girl with
localized scleroderma at the age of 5 years old has con-
secutively developed SLE with lupus nephritis, secondary
antiphospholipidic syndrome, microangiopathic haemo-
lytic anaemia, diffuse interstitial pulmonary fibrosis and
pulmonary hypertension. Another SIgAD patient with a
polyarthritis onset at the age of 14 developed over sev-
eral years features of other connective tissue diseases,
fulfilling the criteria of MCTD. Worthy of attention also
are the sisters with systemic vasculitis from an early age
with associated unclassified hypogammaglobulinaemias
before immunosuppressive treatment was initiated, of
which one had two stroke events at the age of 4 and re-
current cranial nerve palsies and the other had a severe
episode of gastrointestinal haemorrhage. They could not
be considered common variable immunodeficiency disor-
ders (CVID) because total serum IgG levels were not con-
stantly reduced below 500 mg/dl, even though patient 6
developed a variety of autoimmune manifestations charac-
teristic of CVID according to recent relevant literature
[30], including persistent autoimmune thrombocytopenia,
livedo reticularis with negative APLAs, splenomegaly,
nodular regenerative hyperplasia of the liver, skin lesions
with histopathological pattern of interstitial granuloma-
tous dermatitis in association with vasculopathy. The re-
cently described genetic disorder “deficiency of ADA2” is
being considered in both sisters, but yet unproven [31].
Unlike patients with SLE, systemic vasculitis and both
patients with MCTD and SLE/scleroderma overlap syn-
drome, recurrent infectious events were not associated
with PIDs in our JIA patients. We would like to stress
that the available observation period for some of the JIA
patients with PID (patient 5, 13 and 16) was relatively
short. But, as it has been suggested before, the auto-
immunity may be the only manifestation of a PID and
that the absence of repeated infections is not sufficient
to exclude a PID [4]. Conversely, another matter of con-
cern is the confounding impact of longer duration of
follow up after diagnosis in developing infections. That
by itself may have been increased the risk of infections
in some patients (patient 1 and 4) due to longer im-
munosuppressive therapies and hospitalizations.
A better understanding of this paradoxical relationship
between autoimmunity and immunodeficiency is needed
in order to provide more explanations about the contri-
butions of PID to disease expressivity. Until than, the
most relevant aspect of this relationship for the clinician
remains the implications of PID identifying in the
follow-up of these patients, which can be quite diverse
and individualistic. Patients with a known complement
deficiency should be carefully monitored for develop-
ment of other potential complications or associated con-
ditions involving complement activation. For instance, in
a large cohort of C2-deficient SLE patients with long-term
follow-up, a high frequency of severe cardiovascular dam-
age was found that could not be explained by common
risk factors [32]. Moreover, clinical situations of PID with
overlap between increased susceptibility to infection and
autoimmunity may require special considerations in select-
ing the immunosuppressive and biologic therapy, patient
education and clinical monitoring. Finally, the immuno-
globulin therapy, the mainstay of treatment for primary
hypogammaglobulinemias with decreased IgG production,
has also proved to be efficacious in specific autoimmune
and inflammatory diseases [33].
To our knowledge, the co-existing of autoimmune
hepatitis type 1, SLE and PIDs (SIgAD or C4AD) that
we have encountered in patient 2 and 15, has not been
reported in the literature so far. There have been few re-
ported cases of either AIH associated with SLE [34–37]
or AIH and SIgAD [38] or AIH and C4 deficiency [39]
or AIH, SIgAD and primary Sjogren’s syndrome [40]. Be-
tween the two types of AIH, type 1 seems to be more often
associated with other autoimmune diseases, while type 2
presents more commonly with IgA deficiency [41]. We ac-
knowledge that AIH type 1 diagnosis in our SLE patients
was made only on clinical, biochemical and serologic data
and that the liver biopsy for a definitive diagnosis of AIH
has not been done for objective reasons.
Conclusion
In conclusion, a significant number of our JIA patients
had genetic evidence for C2D or C4D and all of them
have exhibited an aggressive disease. However, further
studies are needed to decipher the implications of this
association on disease expression and outcome of these
patients. Moreover, most of our patients with primary
antibody deficiencies including SIgAD and unclassified
hypogammaglobulinaemias showed a more complicated
and severe disease course and even the co-occurrence of
two autoimmune diseases (SLE/scleroderma overlap syn-
drome and SLE/AIH type 1 overlap). We also report the
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first two cases of SLE/AIH type 1 overlap associated with
SIgAD and C4AD, respectively. Our findings among others
demonstrate that complement and immunoglobulin im-
munodeficiencies need careful consideration in patients
with ARDs, as they are common and might contribute to a
more severe clinical course of the disease.
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